Kate Bingham

 

Kate Bingham

Managing Partner

Email
kate.bingham@svlsa.com

 

Sector
Biotechnology

 

Assistant
Paul Kilpatrick

EmailAssistants Email
paul.kilpatrick@svlsa.com

 

EmailPhone
Tel: +44 20 7421 7071

 

EmailOffice

London

Kate Bingham joined SVLS in 1991.

 

Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Affinium, Alantos, Auxilium, Convergence, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, MedNova, Micromet, Oncoethix, PowderMed, RespiVert and Vantia and current investments including Atopix, Autifony, Bicycle, Calchan, Kalvista, Karus, Pulmocide, TopiVert and VHSquared.

 

Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA.

Current Board Seats

 

Autifony Therapeutics
Bicycle Therapeutics
Calchan Holdings
Pulmocide

Responsible for current investments in

 

Atopix Therapeutics/Oxagen
Kalvista Pharmaceuticals
Karus Therapeutics
TopiVert
Vantia Pharmaceuticals
VHsquared

 

Previous Board Seats

 

Alantos Pharmaceuticals
Auxilium Pharmaceuticals

Convergence Pharmaceuticals
ESBATech 
Kinetix Pharmaceuticals
KuDOS Pharmaceuticals
LeukoSite
MedNova
Micromet

Oncoethix
PowderMed
RespiVert

External Board Seats BVCA

 

BVCA